| Name | Title | Contact Details |
|---|
AmMed Direct is a Antioch, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Anavasi Diagnostics is a medical technology company focused on saving lives by developing novel molecular diagnostic testing using a proprietary patent-pending reverse transcriptase methodology. It was founded by world-leading university researchers, top medical device and clinical diagnostics engineering and design executives, manufacturing experts and a former Microsoft software veteran. Throughout their careers, the team has altogether been responsible for the introduction of more than forty medical/diagnostic products and over 350 peer-reviewed research publications.
Alabama Healthcare Equipment is a Muscle Shoals, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are an industry leader in the medical device market with a diverse product range including advanced automatic injection devices for drug delivery and innovative blood sampling products including lancets, lancing devices and safety lancets. Established in 1952 by Ivan Owen and John Mumford, we have almost 70 years of experience with offices, manufacturing sites and distributors located around the globe. Our corporate headquarters are located in Woodstock, Oxford UK. We are dedicated to providing innovative healthcare solutions for the management of a variety of medical conditions. With one of the most advanced global research, design and manufacturing capabilities that delivers innovation successfully to improve quality of life, encourage patient compliance, prevent infection and reduce healthcare costs; making a world of difference to a world of people.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.